{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:13:14Z","timestamp":1791184394453,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental and Toxicologic Pathology"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.etp.2009.08.009","type":"journal-article","created":{"date-parts":[[2009,9,25]],"date-time":"2009-09-25T16:40:33Z","timestamp":1253896833000},"page":"607-613","source":"Crossref","is-referenced-by-count":13,"title":["Mechanism of subendocardial cell proliferation in the rat and relevance for understanding drug-induced valvular heart disease in humans"],"prefix":"10.1016","volume":"62","author":[{"given":"Mark R.","family":"Fielden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Hassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirdesh","family":"Uppal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Day-Lollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Button","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee S.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingrong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle L.","family":"Kolaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.etp.2009.08.009_bib1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/0002-8703(74)90251-8","article-title":"Cardiac murmurs and endocardial fibrosis associated with methysergide therapy","volume":"88","author":"Bana","year":"1974","journal-title":"Am Heart J"},{"key":"10.1016\/j.etp.2009.08.009_bib2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/sj.bjp.0702632","article-title":"RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist","volume":"127","author":"Bonhaus","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.etp.2009.08.009_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.etp.2009.08.009_bib4","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/0192623307312707","article-title":"Cardiac valvular pathology: comparative pathology and animal models of acquired cardiac valvular diseases","volume":"36","author":"Donnelly","year":"2008","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.etp.2009.08.009_bib5","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1093\/eurheartj\/ehm263","volume":"28","author":"Droogmans","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.etp.2009.08.009_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.etp.2008.03.005","article-title":"5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats","volume":"60","author":"Elangbam","year":"2008","journal-title":"Exp Toxicol Pathol"},{"key":"10.1016\/j.etp.2009.08.009_bib7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1369\/jhc.4A6500.2005","article-title":"5-Hydroxytryptamine (5HT) receptors in the heart valves of cynomolgus monkeys and Sprague-Dawley rats","volume":"53","author":"Elangbam","year":"2005","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.etp.2009.08.009_bib8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/01926230290105703","article-title":"Endocardial myxomatous change in Harlan Sprague-Dawley rats (Hsd:S-D) and CD-1 mice: its microscopic resemblance to drug-induced valvulopathy in humans","volume":"30","author":"Elangbam","year":"2002","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.etp.2009.08.009_bib9","first-page":"795","article-title":"A new role for an old molecule: serotonin as a mitogen","volume":"272","author":"Fanburg","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.etp.2009.08.009_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","article-title":"Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.etp.2009.08.009_bib11","first-page":"F922","article-title":"Serotonin 5-HT2A receptor induces TGF-beta1 expression in mesangial cells via ERK: proliferative and fibrotic signals","volume":"276","author":"Grewal","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.etp.2009.08.009_bib12","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/01.CIR.0000159356.42064.48","article-title":"Long-term serotonin administration induces heart valve disease in rats","volume":"111","author":"Gustafsson","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.etp.2009.08.009_bib13","first-page":"454","article-title":"Mitogenic and secretory responses of human valve interstitial cells to vasoactive agents","volume":"9","author":"Hafizi","year":"2000","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.etp.2009.08.009_bib14","first-page":"235","article-title":"Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature","volume":"5","author":"Hendrikx","year":"1996","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.etp.2009.08.009_bib15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejphar.2005.03.010","article-title":"Agonism at 5-HT2B receptors is not a class effect of the ergolines","volume":"513","author":"J\u00e4hnichen","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.etp.2009.08.009_bib16","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0002-9440(10)64489-6","article-title":"Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells","volume":"161","author":"Jian","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.etp.2009.08.009_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/CIRCULATIONAHA.105.554667","article-title":"Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice","volume":"113","author":"Mekontso-Dessap","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.etp.2009.08.009_bib18","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1124\/mol.107.034926","article-title":"Missing links: mechanisms of protean agonists","volume":"71","author":"Neubig","year":"2007","journal-title":"Mol Pharm"},{"key":"10.1016\/j.etp.2009.08.009_bib19","first-page":"256","article-title":"Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves","volume":"9","author":"Roy","year":"2000","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.etp.2009.08.009_bib20","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.etp.2009.08.009_bib21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/335254a0","article-title":"Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein","volume":"335","author":"Seuwen","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.etp.2009.08.009_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0025-6196(11)62328-8","article-title":"Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years","volume":"77","author":"Simula","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.etp.2009.08.009_bib23","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0022-3565(25)12346-X","article-title":"Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences","volume":"276","author":"Wainscott","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.etp.2009.08.009_bib24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1161\/01.RES.0000136520.07995.aa","article-title":"Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease","volume":"95","author":"Walker","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.etp.2009.08.009_bib25","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1164\/rccm.200302-264OC","article-title":"Proliferation and signaling in fibroblasts","volume":"170","author":"Welsh","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.etp.2009.08.009_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Experimental and Toxicologic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0940299309002346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0940299309002346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T10:30:52Z","timestamp":1739356252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0940299309002346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0940299309002346"],"URL":"https:\/\/doi.org\/10.1016\/j.etp.2009.08.009","relation":{},"ISSN":["0940-2993"],"issn-type":[{"value":"0940-2993","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}